HALOG by Bristol Myers Squibb is clinical pharmacology topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
HALOG is a topical corticosteroid ointment developed by Bristol Myers Squibb for dermatological use. It works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms, with absorption and metabolism similar to systemic corticosteroids. The drug is currently in pre-launch stage as an NDA small molecule.
Pre-launch stage with minimal current uptake signals limited immediate commercial team scaling, but launch preparation roles are likely active.
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study of the Role of Top-down Processes in Neuronal Reorganization and Recovery From Sensory Loss: an Exploratory Behavioral and Electroencephalographic Study in Cochlear-supported Deaf Patients
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
Development of Electroencephalography (EEG) and Magnetoencephalography (MEG) Source Reconstruction With Fast Multipole Method
Distinguishing Alcohol Intoxication, Cannabis Intoxication and Co-intoxication Using Electroencephalography (EEG)
Safety and Performance Study of the Electroencephalographic Recording Device and Sound Emissions
Worked on HALOG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on HALOG presents a pre-launch career opportunity in a mature therapeutic category with significant competitive pressure. Success will require strong launch execution and clear differentiation strategy to achieve market penetration in a generic-dominated segment.